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Introduction: Low-dose computed tomography (LD-CT) screen-
ing can reduce lung cancer mortality; however, it is essential to 
improve nodule management protocols. We analyze the perfor-
mance of the diagnostic protocol of the Continuous Observation of 
SMOking Subjects single-center screening study, after long-term 
follow-up.
Methods: Between 2004 and 2005, 5203 asymptomatic high-risk 
individuals (≥20 pack-years, aged 50 years or older) were enrolled 
to undergo annual LD-CT for 5 years. Nodules 5 mm or smaller 
underwent repeat LD-CT a year later. Nodules larger than 5.0 mm 
and 8.0 mm or smaller received LD-CT 3 to 6 months later. Nodules 
larger than 8.0 mm or growing underwent CT-positron emission 
tomography. True positives were any stage prevalent lung cancer, 
progressing nodules diagnosed at stage 1, localized multifocal can-
cer, or new nodules diagnosed at any stage. False negatives were pro-
gressing nodules diagnosed at stage >1. False positives were benign 
nodules resected surgically.
Results: Compliance was 79% over 5 years; 175 primary lung can-
cers were detected (0.76% per year), 136 (77.7%) were N0M0 and 
three were interval cancers. Eleven second primary lung cancers 
were diagnosed. Resectability was 87.4%; postoperative mortality 
0.6%. Recall was 6.4% overall, 10.1% at baseline. False negatives 
were 14 of 175 (8%). Protocol sensitivity was 158 of 175 (90%); 
specificity 4994 of 5028 (99.4%); positive predictive value was 158 
of 187 (84.5%); and negative predictive value was 4994 of 5016 
(99.7%). Twenty-nine of 204 (14.2%) benign lesions were diagnosed 
surgically. Five-year overall and cancer-specific survival were 78% 
(95% confidence interval, 72–84) and 82% (95% confidence interval, 
76%–88%) respectively.
Conclusions: The performance of the CT protocol was satisfactory 
with an acceptable number of benign lesions biopsied surgically, low 
recall rate, and good oncological outcomes. However, interval and 
advanced cancers, and misdiagnoses, need to be reduced, perhaps by 
risk modeling and use of serum markers.
Key Words: Lung cancer, Computed tomography, Screening, 
Surgery.
(J Thorac Oncol. 2014;9: 935–939)
Early detection is essential for successful lung cancer treatment.1 During the last 15 years, several studies 
have shown that low-dose computed tomography (LD-CT), 
without contrast, can reliably diagnose lung nodules of a 
few millimeters in diameter in asymptomatic individuals 
at high risk of developing lung cancer.2–7 The randomized 
National Lung Screening Trial (NLST)8 demonstrated a 
20% mortality reduction in the CT-screened arm compared 
with the chest radiograph-screened arm, providing clear 
data to inform the long-running debate on the effective-
ness of LD-CT screening for lung cancer.9–13 However, not-
withstanding these encouraging oncological results, most 
studies have found that many screening-detected nodules 
are benign, but often require invasive investigations, with 
attendant increased costs and risk of complications, to dem-
onstrate nonmalignancy.8,9,13,14 This poor specificity may 
constitute an obstacle to the large-scale  implementation of 
screening.
Few studies have assessed the diagnostic performance 
of the LD-CT screening protocols,2,14–18 mainly because the 
major screening trials are multicentric, introducing consider-
able heterogeneity to nodule management, and have focused 
more on oncological results than invasive procedures.8 
Guidelines for the management of small CT-detected nodules 
have recently been proposed by the Fleischner society16 but 
pertain to nonscreened subjects.
Our aim in this study is to assess the performance, inva-
siveness, and side effects of the screening protocol of our non-
randomized LD-CT screening study on high-risk individuals 
(Continuous Observation of SMOking Subjects [COSMOS]) 
in the light of long-term follow-up.
MATERIALS AND METHODS
Between October 2004 and October 2005, 5203 
asymptomatic high-risk (smoking history ≥20 pack-years) 
individuals aged 50 years or older were enrolled in the 5-year 
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single-center COSMOS study and underwent baseline mul-
tidetector LD-CT for lung cancer, followed by four annual 
repeat scans. Screening protocol, enrollment criteria, LD-CT 
settings, and diagnostic algorithm are described elsewhere.15 
The study was approved by the ethics committee of the 
European Institute of Oncology and participants provided 
written informed consent.
Supplementary Table 1 (Supplementary Digital 
Content, http://links.lww.com/JTO/A600) shows the diag-
nostic workup for nodules, developed during the first 3 
years of the study. From 2007, lung resections were per-
formed using a minimally invasive (mainly robot assisted) 
approach.
We compared the rate of invasive procedures for 
benign disease with that for nonscreened patients attending 
the Division of Thoracic Surgery of our institute during the 
same period. Smoking was investigated by a self-reporting 
questionnaire completed at baseline and each annual visit. 
Only in the fifth year did we step-up antismoking activity, 
opening a tobacco control unit for COSMOS participants at 
our institute.
Statistical Analysis
On the basis of pathological findings or at least 12 
months of follow-up, we assessed the performance of the diag-
nostic protocol by determining (1) true positives as: any stage 
prevalent lung cancer, growing nodules diagnosed at stage 1, 
localized multifocal cancer, or new nodules diagnosed at any 
stage; (2) false negatives as: growing nodules diagnosed as 
lung cancer at stage >1 (excluding localized multifocal can-
cer); (3) false positives: as benign nodules resected surgically; 
and (4) true negatives: as nongrowing nodules at baseline and 
subsequently.
From these data, the sensitivity and specificity of the 
protocol for the entire cohort and for subgroups defined by 
sex, age, and smoking history were estimated. Fisher’s exact 
test was used to compare groups. Survival was represented by 
Kaplan–Meier curves. Mortality due to lung cancer, cardio-
vascular disease, nonlung cancer, and other causes was also 
determined. The analyses were performed with SAS, version 
8.2 (Cary, NC). All p values are two sided.
RESULTS
The median age of the 5203 participants was 57 years 
(range, 50–84); median tobacco consumption was 44 pack-
years (interquartile range, 36–60; range, 20–260). Table 1 
shows compliance, recalls for further investigation, number 
of cancers detected, proportion with localized N0M0 disease, 
positron emission tomography (PET)-CT–positive cases, and 
nonsolid nodules, according to screening round.
Two hundred four invasive diagnostic procedures were 
performed for suspected cancer. Primary lung cancer was 
diagnosed in 175 patients: 55 at baseline, 117 at subsequent 
rounds, and three as symptoms-detected interval cancers (all 
small-cell disease); 11 of 175 patients (6.3%) had a second 
primary (metachronous) lung cancer.
The study had 23,116 person-years of observation, with 
an overall lung cancer detection rate of 0.76 per 100 person-
years (range 0.3%–1.1%) during the 5 study years. Localized 
cancer (N0M0) was diagnosed in 136 of 175 cases (78%) 
and varied from 68% to 87% during the 5 years (Table 1). 
Radical resection was achieved in 153 of 175 cases (87%): 
pneumonectomy was performed in three, lobectomy in 135, 
and sublobar resection in 15. Radical lymph node dissection 
was performed in 145 of 175 cases. Three patients received 
exploratory thoracotomy, and were not resected due to pleural 
carcinosis. Robot-assisted lobectomy or segmentectomy was 
performed in 43 and five cases, respectively. Minor postop-
erative/postbiopsy complications occurred in 34 cases (19%) 
and major complications in 12 cases (7%). Thirty-day and 
90-day postoperative mortality were both 0.6% (1 patient 
died of acute respiratory distress syndrome). Multifocal dis-
ease was found in 16 of 175 patients (9.1%) who had 5-year 
survival of 81% (Supplementary Figure 1, Supplementary 
Digital Content, http://links.lww.com/JTO/A600). There were 
129 adenocarcinomas (73.7%), 20 squamous-cell carcinomas 
(11.4%), 14 other non–small-cell lung cancers (8.0%), and 12 
small-cell lung cancers (6.9%).
Surgery revealed benign lung disease in 29 of 204 
(14.2%), one of whom had a grade 1 postoperative compli-
cation (prolonged air leak), but there was no 30- or 90-day 
mortality. Characteristics of the pathologically proven benign 
nodules are reported in detail elsewhere.19 A nonsurgical 
TABLE 1.  Characteristics of Study Participants and First Primary Lung Malignancies Detected, with Compliance, Recall Rate, 
Detection Rate, Stage at Diagnosis, PET-Positive Cases, and Nonsolid Cases According to Year of Screening
Screening 
Round
Total Participants
Recalled for 
CT or PET
Recalled for 
PET
First Primary 
Lung Cancer
Localized 
Cancer (N0M0)
Mean  
Size
PET  
Positive
Nonsolid 
Nodule
N (%) N (%) N (%) N (%) N (%) mm (SD)* N (%) N (%)
Baseline 5203 (100) 525 (10.1) 160 (3.1) 55 (1.06) 43 (78.2) 20.6 (13.6) 48 (87.3) 4 (7.3)
2nd 4822 (93) 189 (3.9) 68 (1.4) 38 (0.79) 26 (68.4) 13.6 (7.2) 26 (68.4) 5 (13.2)
3rd 4583 (88) 232 (5.1) 74 (1.6) 39 (0.85) 34 (87.2) 12.4 (7.5) 11 (28.2) 13 (33.3)
4th 4385 (84) 289 (6.6) 62 (1.4) 31 (0.71) 23 (74.2) 18.6 (18.6) 21 (67.7) 6 (19.4)
5th 4123 (79) 241 (5.8) 66 (1.6) 12 (0.29) 10 (83.3) 11.0 (4.5) 5 (41.7) 2 (16.7)
Whole period (23,116 person-years of 
observation)
1476 (6.4) 430 (1.9) 175 (0.76) 136 (77.7) 16.2 (12.5) 111 (63.4) 30 (17.1)
Preoperative size used when pathologic size missing.
PET, positron emission tomography; CT, computed tomography.
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diagnostic procedure for benign disease was performed in 12 
patients: nine received simple bronchoscopy and three trans-
thoracic needle biopsy. Patients with malignant disease, can-
didates for induction or definitive chemotherapy, underwent 
mediastinoscopy in eight cases, video-assisted mediastinal 
lymph node biopsy in one case, and CT-guided fine-needle 
aspiration biopsy in nine cases. Only seven patients, candi-
dates for surgical resection as first intervention, underwent 
invasive diagnostic procedures such as bronchoscopy6 or 
transthoracic needle biopsy2 before surgery.
Supplementary Table 2 (Supplementary Digital Content, 
http://links.lww.com/JTO/A600) shows the characteristics of 
the 14 of 175 cases (8%) with delayed diagnoses in the first 5 
years of screening. Volume-doubling time was 161 days. Five 
cases had a nodule 5 mm or smaller the year before (protocol 
failure), three had very fast-growing small-cell disease (lead-
time bias), five had a central lesion (diagnostic algorithm fail-
ure), and in three, the nature of the lesion was misinterpreted 
(human failure). More than one of these situations occurred 
in two patients.
Protocol sensitivity, specificity, positive predictive 
value, and negative predictive value were 90.3%, 99.4%, 
84.5%, and 99.7%, respectively. The accuracy of the surgical 
protocol was 175 of 204 (85.8%) with 29 surgical operations 
for benign disease (Table 2). Analysis of the subgroup satisfy-
ing NLST entry criteria showed sensitivity 88.5%, specificity 
99.2%, positive predictive value 83.9%, and negative predic-
tive value 99.5% similar to those of the entire group (Table 3).
Follow-up was available for all except five patients who 
were lost to follow-up. After a median of 5.2 years, Kaplan–
Meier overall 5-year survival in the 175 patients was 78% 
(95% confidence interval, 72–84) (Fig. 1). Overall and lung 
cancer–specific survival is shown by stage in Supplementary 
Figure 2 (Supplementary Digital Content, http://links.lww.
com/JTO/A600). A total of 136 screened individuals died: 28 
of lung cancer, 41 of cardiovascular disease, 38 of extrapul-
monary malignancy, 11 of other causes, and 18 of unknown 
causes.
During follow-up, 11 of 175 patients with first primary 
lung cancer developed a second (metachronous) primary lung 
cancer. Survival for this subgroup is shown in Supplementary 
Figure 3 (Supplementary Digital Content, http://links.lww.
com/JTO/A600). Applying individual baseline lung cancer 
risk probability calculated according to the COSMOS risk 
model20 to the person-years accumulated from first primary 
diagnosis to date of fifth annual CT, we expected 10.4 second 
primary lung cancers. Average annual lung cancer risk proba-
bility for the 175 participants diagnosed with lung cancer dur-
ing the first 5 screening years was 1.7% at baseline compared 
with 1.2% for the whole screened population.
During the study period (2004–2009), we performed 
1571 lung resections at our institute for suspicious lung 
lesions detected in the nonscreening setting; of these, 342 
(21.7%) were benign.
DISCUSSION
Despite the landmark finding of the NLST that screen-
ing reduces mortality,8 the problems of high cost and risk of 
false positives remain and constitute a potential obstacle to the 
large-scale implementation of LD-CT screening for lung can-
cer.9,10,13,19,21 The false-positive rate is particularly problematic 
as these nodules have to be investigated, increasing expense 
TABLE 2.  Performance of Screening Process Including Diagnostic Protocol: Entire Population
Observed Outcome
No cancer Cancer Total
Predicted outcome No cancer 4999 (true negative)a 17 (false negative)c 5016
Cancer 29 (false positive)b 158 (true positive)d 187
Total 5028 175 5203
aA total of 4999 persons had either no nodule or nongrowing nodules followed over time.
bTwenty-nine persons had surgery for suspected lung cancer but had a benign nodule.
cFourteen persons with pre-existing nodules had delayed surgery (diagnosed with “advanced” lung cancer at subsequent screening) and three were diagnosed with interval cancer.
dOne hundred fifty-eight persons had surgery for suspected lung cancer.
TABLE 3.  Performance of Screening Process Including Diagnostic Protocol: Analysis Restricted to Persons Who Satisfied NLST 
Entry Criteria (3061 Persons of Age >55 yr, Who Smoked >30 Pack-Years)
Observed Outcome
No cancer Cancer Total
Predicted outcome No cancer 2909 (true negative)a 15 (false negative)c 2924
Cancer 22 (false positive)b 115 (true positive)d 137
Total 2931 130 3061
aA total of 2909 persons had either no nodule or nongrowing nodules followed over time.
bTwenty-two persons had surgery for suspected lung cancer but had a benign nodule.
cThirteen persons with pre-existing nodules had delayed surgery (diagnosed with “advanced” lung cancer at subsequent screening) and two were diagnosed with interval cancer.
dOne hundred fifteen persons had surgery for suspected lung cancer.
NLST, National Lung Screening Trial.
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and resource utilization, and often causing unnecessary mor-
bidity, with reduced acceptance of screening among at-risk 
individuals.5,8,9
Standardized algorithms aim to find a middle way 
between a too invasive workup, with high proportions of use-
less procedures and risk of overtreatment, and too lax sur-
veillance, resulting in too many delayed diagnoses. Various 
protocols have been proposed.18,22,23 Some2–4 like us17 have 
adopted maximum nodule diameter of 5 mm as threshold for 
further investigation. The Fleischner Society guidelines sug-
gested 4 mm as cutoff,16 and this threshold was also adopted 
by the NLST, which however had a very high recall rate.8 
Other investigators have introduced volume instead of maxi-
mum diameter14,24 for more precise evaluation of growth.
Because a high proportion (79%) of our recruited par-
ticipants attended for the five screening rounds, we conclude 
that screening was well accepted. The nodule workup protocol 
used in COSMOS was modified during the study as we gained 
experience.18 The proportion of participants undergoing fur-
ther examinations was acceptable at 6.4%, which is lower than 
that reported in other nonrandomized studies 3–5,23 and also 
lower than the 23% recall rate for the CT arm of NLST.8
Only 29 participants (14% of those with suspicious 
nodules) underwent surgical biopsy for benign disease dur-
ing the first 5 years of COSMOS. This figure is considerably 
lower than the 21% of non–screening-detected suspicious 
nodules subjected to surgical biopsy at our institute during the 
same period (mainly because surgeons were not constrained 
by a diagnostic algorithm) and translates to only one of 769 
(0.13%) of screened participants per year. We maintain that 
this is an acceptable figure, particularly because biopsies were 
performed at a specialized high-volume center mostly using 
a minimally invasive technique. To limit anxiety among par-
ticipants requiring recall, we contacted them personally before 
sending the recall notice.
Only in 14 cases, lesions were misdiagnosed (present on 
the scan taken the year previously). Five of these lesions were 
centrally located, three were fast growing (all small-cell can-
cers), and in five, the nodule, the previous year, was less than 
5 mm and thus did not undergo further evaluation. However, if 
we had lowered the cutoff to 4 mm, as in the NLST,8 the recall 
rate would have been excessively high. In three cases, diagnosis 
was delayed because the lesion was not recognized on the ear-
lier LD-CT. It is noteworthy that delayed/misdiagnoses received 
scant attention in the numerous lung cancer screening studies 
published during the last decade. The New York-Early Lung 
Cancer Action Project (NY-ELCAP) study23 reported that 10% 
cancers had delayed diagnosis similar to our figure of 8%.
It is encouraging that sensitivity (90.3%) and specificity 
(99.4%) were high for first 5 years of COSMOS, and also that 
78% of the cancers diagnosed were localized (N0M0). A high 
proportion (87%) of cancers were treated curatively, and long-
term oncological results were good (overall 5-year survival 
78%; 95% confidence interval, 72–84). Similar results were 
obtained when we restricted the analysis to the subgroup sat-
isfying NLST inclusion criteria (higher-risk population). The 
less restrictive criteria that guided recruitment into the present 
study compared with the NLST did not increase screening-
related risks in terms of invasive procedures and false-posi-
tive cases and did not change the diagnostic performance of 
screening.
Except for the Nelson trial,14 all other studies8,23,24 
defined false positives as those with an indeterminate nodule 
found at a single scan. By contrast, we considered false posi-
tives to be those treated by surgical biopsy for what turned out 
to be benign disease. Because the great majority of indetermi-
nate lung nodules are found benign after a simple noninvasive 
examination (typically repeat LD-CT 3 or 6 months later), 
they should be classified simply as indeterminate nodules. Our 
change in definition greatly increases screening specificity.
In a previous COSMOS article,25 we assessed the utility 
of PET-CT for diagnosing indeterminate lung nodules found 
at baseline. For solid nodules larger than 1 cm, PET sensitiv-
ity was 100% and specificity 90%, when maximum standard 
uptake value of greater than 2.0 was considered positive. 
However, for cancers detected in subsequent rounds, PET sen-
sitivity was considerably lower, mainly because the proportion 
of small-size and ground-glass nodules was greater (Table 1). 
FIGURE 1.  Overall and lung cancer–
specific survival of patients diagnosed 
with lung cancer in screening cohort 
(42 deaths occurred, 35 attributed to 
lung cancer after a median follow-up of 
5.2 years). CI, confidence interval.
Overall survival Lung cancer-specific survival
N patients at risk N patients at risk
175 162 151 143 127 97 64 33 3 175 162 151 143 127 97 64 33 3
Overall survival (95% CI) Lung cancer specific survival (95% CI)
1-year 2-year 3-year 5-year 1-year 2-year 3-year 5-year
93 (89-96) 86 (81-91) 83 (78-89) 78 (72-84) 93 (89-97) 87 (82-92) 85 (80-90) 82 (76-88)
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Additional data are required to elucidate the role of PET-CT in 
the diagnostic protocol of screen-detected nodules.
The main limitation of the COSMOS study is that it 
lacks a control group. When we were planning the study, we 
considered having a chest radiograph control group or also a 
no-screening group. We dismissed both as unethical—chest 
radiograph because it was already known that LD-CT is 
much more sensitive than chest radiograph for detecting lung 
malignancies.2 A potential limitation of screening in general 
is overdiagnosis. We estimated that approximately 10% of 
cancers diagnosed and resected in COSMOS study were indo-
lent based on a volume-doubling time of 600 or more days.19 
Notwithstanding the encouraging results of the COSMOS 
workup protocol for indeterminate nodules detected at LD-CT 
screening (particularly low recall and delayed diagnosis rates 
compared with good long-term survival of patients with 
screening-detected cancers), it is clear that workup still needs 
to be improved. One way of doing this would be to tailor the 
screening interval to the risk of an individual subject devel-
oping cancer, as determined by a risk-evaluation algorithm.20 
It is also important to determine whether very early lung 
cancers can be safely treated by more conservative surgical 
approaches.26 Finally, the utility of molecular serum markers 
for the early detection of lung cancer in heavy smokers27 needs 
to be established.
These uncertainties should not, however, be seen as 
an obstacle to the large-scale implementation of lung cancer 
screening in Europe, as suggested by others.28 Approximately 
269,000 deaths from lung cancer are expected in Europe in 
2014, and although antismoking campaigns are having an 
effect and must be continued, it is now clear that screening 
can contribute to reducing lung cancer mortality.
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